The Cardiovascular diseases (CVDs) continue to be a leading global health challenge, requiring innovative pharmacological strategies for effective management. Recent advancements in medication use for CVD focus on integrating novel therapeutic agents, refining guideline-directed medical therapy (GDMT), and addressing treatment disparities. The Recent approval of Semaglutide for weight management in cardiovascular patients highlights the importance of obesity control in reducing cardiovascular risks. Innovations such as sodium-glucose co-transporter 2 (SGLT2) inhibitors and angiotensin receptor-neprilysin inhibitors (ARNIs) have redefined heart failure management, improving morbidity and mortality outcomes. Despite these advances, gaps in care persist, particularly in the under treatment of women with coronary artery disease and the inappropriate use of Aspirin for primary prevention in older adults. Comprehensive pharmacotherapy now emphasizes tailored combinations of antiplatelet agents, anticoagulants, statins, and blood pressure-lowering medications. Emerging therapies, including chelation therapy, hold potential but require further validation.